Cargando…

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced DIC

Detalles Bibliográficos
Autores principales:	Yamakawa, K, Ogura, H, Fujimi, S, Morikawa, M, Ogawa, Y, Umemura, Y, Inoue, Y, Tanaka, H, Hamasaki, T, Shimazu, T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068753/ http://dx.doi.org/10.1186/cc13433

Ejemplares similares

Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yoshimura, Jumpei, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2013)

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study
por: Yamakawa, Kazuma, et al.
Publicado: (2011)

Impaired balance between coagulation and fibrinolysis plays a prominent role in patients with sepsis
por: Umemura, Y, et al.
Publicado: (2014)

Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients
por: Miyoshi, Seigo, et al.
Publicado: (2014)

Efficacy of recombinant human soluble thrombomodulin in disseminated intravascular coagulation
por: Yasuda, T, et al.
Publicado: (2010)

Age-related differences in the survival benefit of the administration of antithrombin, recombinant human thrombomodulin, or their combination in sepsis
por: Wada, Takeshi, et al.
Publicado: (2022)

Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis
por: Yamakawa, Kazuma, et al.
Publicado: (2019)

Clinical efficacy of recombinant human soluble thrombomodulin in patients with septic disseminated intravascular coagulation
por: Suzuki, Y, et al.
Publicado: (2013)

Concomitant Versus Individual Administration of Antithrombin and Thrombomodulin for Sepsis-Induced Disseminated Intravascular Coagulation: A Nationwide Japanese Registry Study
por: Umemura, Yutaka, et al.
Publicado: (2018)

Efficacy of recombinant thrombomodulin for DIC after deceased donor liver transplantation: a case report
por: Kimura, Koichi, et al.
Publicado: (2016)

Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin
por: Wada, Hideo, et al.
Publicado: (2023)

Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan
por: Yamakawa, Kazuma, et al.
Publicado: (2016)

Recombinant human thrombomodulin for pneumonia-induced severe ARDS complicated by DIC in children: a preliminary study
por: Hirata, Naoyuki, et al.
Publicado: (2021)

Comparison of the effects of recombinant human soluble thrombomodulin for systemic inflammatory response syndrome-associated coagulopathy with and without continuous hemodiafiltration
por: Matsuo, SM, et al.
Publicado: (2011)

Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy
por: Levi, Marcel, et al.
Publicado: (2020)

Efficacy of Carbapenems Compared With Noncarbapenem Broad-Spectrum Beta-Lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis: A Nationwide Observational Study*
por: Umemura, Yutaka, et al.
Publicado: (2023)

Clinical Impact of Recombinant Soluble Thrombomodulin for Disseminated Intravascular Coagulation Associated with Severe Acute Cholangitis
por: Okuda, Atsushi, et al.
Publicado: (2018)

Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model
por: Iba, Toshiaki, et al.
Publicado: (2009)

Efficacy of early administration of thrombomodulin alfa in patients with sepsis-induced disseminated intravascular coagulation: subanalysis from post-marketing surveillance data
por: Eguchi, Y, et al.
Publicado: (2014)

Anticoagulant therapies against sepsis‐induced disseminated intravascular coagulation
por: Umemura, Yutaka, et al.
Publicado: (2023)

Coagulofibrinolytic effects of recombinant soluble thrombomodulin in prolonged porcine cardiac arrest
por: Zhang, Boya, et al.
Publicado: (2023)

Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies
por: Kudo, Daisuke, et al.
Publicado: (2021)

Use of Recombinant Human Soluble Thrombomodulin in Patients with Sepsis-Induced Disseminated Intravascular Coagulation after Intestinal Perforation
por: Tagami, Takashi, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study
por: Kato, Takahiro, et al.
Publicado: (2018)

Recombinant human soluble thrombomodulin is associated with attenuation of sepsis-induced renal impairment by inhibition of extracellular histone release
por: Akatsuka, Masayuki, et al.
Publicado: (2020)

Markers of acute kidney injury in patients with sepsis: the role of soluble thrombomodulin
por: Katayama, Shinshu, et al.
Publicado: (2017)

Non-linear and Interaction Analyses of Biomarkers for Organ Dysfunctions as Predictive Markers for Sepsis: A Nationwide Retrospective Study
por: Umemura, Yutaka, et al.
Publicado: (2022)

Age Is Associated With the Efficacy of Anticoagulant Therapies Against Sepsis-Induced Disseminated Intravascular Coagulation
por: Takahashi, Kyosuke, et al.
Publicado: (2021)

Human Soluble Recombinant Thrombomodulin, ART-123, Resolved Early Phase Coagulopathies, but Did Not Significantly Alter the 28 Day Outcome in the Treatment of DIC Associated with Infectious Systemic Inflammatory Response Syndromes
por: Mori, Shusuke, et al.
Publicado: (2019)

Serial change of C1 inhibitor in patients with sepsis: a preliminary report
por: Hirose, T, et al.
Publicado: (2015)

Adequate application of recombinant thrombomodulin for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki
Publicado: (2015)

Detecting hypercoagulability in sepsis: thromboelastometry vs thrombomodulin-modified thrombin generation test
por: Osovskikh, VV, et al.
Publicado: (2015)

Recombinant human soluble thrombomodulin administration improves sepsis-induced disseminated intravascular coagulation and mortality: a retrospective cohort study
por: Kato, Takahiro, et al.
Publicado: (2013)

Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure
por: Kawano, Noriaki, et al.
Publicado: (2020)

Recombinant Human Soluble Thrombomodulin Suppresses Monocyte Adhesion by Reducing Lipopolysaccharide-Induced Endothelial Cellular Stiffening
por: Okamoto, Takayuki, et al.
Publicado: (2020)

Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis
por: Isshiki, Takuma, et al.
Publicado: (2019)

Protective Effects of Recombinant Human Soluble Thrombomodulin on Lipopolysaccharide-Induced Acute Kidney Injury
por: Nozaki, Yuji, et al.
Publicado: (2020)

Enhanced effect of recombinant human soluble thrombomodulin by ultrasound irradiation in acute liver failure
por: Hoshino, Kota, et al.
Publicado: (2020)

New diagnostic marker for sepsis: soluble CD14 subtype
por: Shirakawa, K, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_sinpjurdsrf5ckiui3vjokqf53